Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine for Angina in Hypertrophic Cardiomyopathy
NCT01721967Phase 4Completed
- Sponsor
- Duke University
- Start
- Nov 2012
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranolazine in hypertrophic cardiomyopathy (HCM), sponsored by Duke University. Primary endpoints: QT Interval at 60 Days, Number of Adverse Events Considered Probably or Possibly Related to Study Drug at 60 Days and 1 more. Started Nov 2012; status: completed.
02
Drugs
ranolazine
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT01721967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01721967.